Efficacy and safety of once‐weekly efpeglenatide in people with suboptimally controlled type 2 diabetes: The AMPLITUDE‐D, AMPLITUDE‐L and AMPLITUDE‐S randomized controlled trials

To evaluate the efficacy and safety of once‐weekly (QW) efpeglenatide in people with type 2 diabetes (T2D) suboptimally controlled with oral glucose‐lowering drugs and/or basal insulin (BI).

[1]  R. Gabbay,et al.  Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). , 2022, Diabetes care.

[2]  R. Mukherjee,et al.  Twenty Years of Insulin Gla-100: A Systematic Evaluation of Its Efficacy and Safety in Type 2 Diabetes Mellitus , 2022, Diabetes Therapy.

[3]  E. Huang,et al.  6. Glycemic Targets: Standards of Medical Care in Diabetes-2022. , 2021, Diabetes care.

[4]  E. Huang,et al.  9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2022. , 2021, Diabetes care.

[5]  R. Pratley,et al.  GLP-1 Analogs and DPP-4 Inhibitors in Type 2 Diabetes Therapy: Review of Head-to-Head Clinical Trials , 2020, Frontiers in Endocrinology.

[6]  J. Rosenstock,et al.  Once-Weekly Efpeglenatide Dose-Range Effects on Glycemic Control and Body Weight in Patients With Type 2 Diabetes on Metformin or Drug Naive, Referenced to Liraglutide , 2019, Diabetes Care.

[7]  W. E. Sanabria,et al.  Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial , 2019, The Lancet.

[8]  V. Tiwari,et al.  Recent updates on GLP-1 agonists: Current advancements & challenges. , 2018, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[9]  A. Consoli,et al.  Glucagon‐like peptide‐1 receptor agonists in type 2 diabetes treatment: are they all the same? , 2018, Diabetes/metabolism research and reviews.

[10]  G. Charpentier,et al.  Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial , 2017, Diabetes Care.

[11]  J. DeVries,et al.  Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial. , 2017, The lancet. Diabetes & endocrinology.

[12]  S. Bain,et al.  Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. , 2017, The lancet. Diabetes & endocrinology.

[13]  Yong-Sung Kim,et al.  Immunoglobulin Fc Heterodimer Platform Technology: From Design to Applications in Therapeutic Antibodies and Proteins , 2016, Front. Immunol..

[14]  F. Giorgino,et al.  Efficacy and Safety of Once-Weekly Dulaglutide Versus Insulin Glargine in Patients With Type 2 Diabetes on Metformin and Glimepiride (AWARD-2) , 2015, Diabetes Care.

[15]  G. Umpierrez,et al.  Efficacy and Safety of Dulaglutide Monotherapy Versus Metformin in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-3) , 2014, Diabetes Care.

[16]  M. Hanefeld,et al.  Beneficial effects of once-daily lixisenatide on overall and postprandial glycemic levels without significant excess of hypoglycemia in type 2 diabetes inadequately controlled on a sulfonylurea with or without metformin (GetGoal-S). , 2014, Journal of diabetes and its complications.

[17]  J. Meier.  GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus , 2012, Nature Reviews Endocrinology.

[18]  A. McCall.  Insulin therapy and hypoglycemia. , 2012, Endocrinology and metabolism clinics of North America.

[19]  A. Garber.  Long-Acting Glucagon-Like Peptide 1 Receptor Agonists , 2011, Diabetes Care.

[20]  F. Porzsolt,et al.  Using machine learning to predict laboratory test results , 2016, Annals of clinical biochemistry.